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Abstract
Background:  Uridine 5'-triphosphate (UTP) and uridine 5'-diphosphate (UDP) act via P2Y
receptors to evoke contraction of rat pulmonary arteries, whilst adenosine 5'-triphosphate (ATP)
acts via P2X and P2Y receptors. Pharmacological characterisation of these receptors in intact
arteries is complicated by release and extracellular metabolism of nucleotides, so the aim of this
study was to characterise the P2Y receptors under conditions that minimise these problems.
Methods: The perforated-patch clamp technique was used to record the Ca2+-dependent, Cl-
current (ICl,Ca) activated by P2Y receptor agonists in acutely dissociated smooth muscle cells of rat
small (SPA) and large (LPA) intrapulmonary arteries, held at -50 mV. Contractions to ATP were
measured in isolated muscle rings. Data were compared by Student's t test or one way ANOVA.
Results: ATP, UTP and UDP (10-4M) evoked oscillating, inward currents (peak = 13–727 pA) in
71–93% of cells. The first current was usually the largest and in the SPA the response to ATP was
significantly greater than those to UTP or UDP (P < 0.05). Subsequent currents tended to decrease
in amplitude, with a variable time-course, to a level that was significantly smaller for ATP (P < 0.05),
UTP (P < 0.001) and UDP (P < 0.05) in the SPA. The frequency of oscillations was similar for each
agonist (mean≈6–11.min-1) and changed little during agonist application. The non-selective P2
receptor antagonist suramin (10-4M) abolished currents evoked by ATP in SPA (n = 4) and LPA (n
= 4), but pyridoxalphosphate-6-azophenyl-2',4'-disulphonic  acid (PPADS) (10-4M), also a non-
selective P2 antagonist, had no effect (n = 4, 5 respectively). Currents elicited by UTP (n = 37) or
UDP (n = 14) were unaffected by either antagonist. Contractions of SPA evoked by ATP were
partially inhibited by PPADS (n = 4) and abolished by suramin (n = 5). Both antagonists abolished
the contractions in LPA.
Conclusion: At least two P2Y subtypes couple to ICl,Ca in smooth muscle cells of rat SPA and LPA,
with no apparent regional variation in their distribution. The suramin-sensitive, PPADS-resistant
site activated by ATP most resembles the P2Y11 receptor. However, the suramin- and PPADS-
insensitive receptor activated by UTP and UDP does not correspond to any of the known P2Y
subtypes. These receptors likely play a significant role in nucleotide-induced vasoconstriction.
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Background
Uridine 5'-triphosphate (UTP) and uridine 5'-diphos-
phate (UDP) act via P2Y receptors, whilst adenosine 5'-tri-
phosphate (ATP) acts via P2X as well as P2Y receptors, to
modulate vascular tone [1-3]. P2X receptors are ligand-
gated cation channels and the ability of the P2X1 subtype
to mediate rapid, transient inward currents in pulmonary
artery smooth muscle cells [4,5] and induce constriction
of the pulmonary vasculature (see [6] and references
therein) has been characterised in some depth. P2Y recep-
tors are G protein-coupled receptors and P2Y agonists act
at smooth muscle receptors to evoke vasoconstriction in
the rat perfused lung at resting tone, but induce vasodila-
tion via endothelial receptors if muscle tone is first raised
[7-10]. Similarly, P2Y agonists are contractile at resting
tone and relaxant at raised tone in isolated branches of rat
intrapulmonary arteries [11-13]. Compared with P2X
receptors much less is known about which of the eight
mammalian P2Y subtypes (P2Y1,2,4,6,11,12,13,14) [14,15] are
expressed in pulmonary vascular smooth muscle or about
the signalling pathways through which they act.
In a previous study [6] we showed that UTP and UDP
both act via two P2Y receptors to evoke contraction of rat
isolated pulmonary arteries. For each agonist one site was
insensitive to the antagonists suramin and pyridoxalphos-
phate-6-azophenyl-2',4'-disulphonic acid (PPADS),
whilst the other was inhibited by suramin, but not
PPADS. UTP is a potent agonist at the P2Y2 and P2Y4
receptors and a weaker agonist at the P2Y6  subtype
[16,17]. Of these three receptors, only the P2Y2  is
suramin-sensitive and PPADS-insensitive [18], so this is
likely to be one of the sites of action of UTP. The molecu-
lar identity of the suramin-and PPADS-insensitive site of
action of UTP is unclear as the P2Y4 and P2Y6 subtypes are
both reported to be antagonised by PPADS, but not
suramin [18-20]. UDP is a potent agonist at the P2Y6
receptor only [16,17]. mRNA for this subtype and
suramin-insensitive contractions to UDP in pulmonary
arteries have been demonstrated [12], but the lack of
effect of PPADS against the contractions evoked by UDP
in our previous study are inconsistent with the P2Y6 recep-
tor.
A number of factors that can complicate the characterisa-
tion of P2Y receptors may have prevented the clear identi-
fication of the P2Y receptors mediating the contractions
seen in previous studies. These include the release of
nucleotides from cells, their breakdown by ecto-nucleoti-
dases and their bioconversion by ecto-nucleoside diphos-
phokinase (eNDPK) [16,21-24]. Thus, as well as a direct
action at the P2Y6 receptor, UTP can also act indirectly,
after dephosphorylation to UDP. Likewise, UDP can be
converted to UTP by eNDPK and so act indirectly at P2Y2
and P2Y4 receptors. At present, potent and selective inhib-
itors of the ecto-enzymes are not available, but one way to
minimise these metabolic problems is to apply the ago-
nists to rapidly perfused, dissociated cells.
The aim of the present study was to extend the pharama-
cological characterisation of the P2Y receptors mediating
pulmonary vasoconstriction, in conditions that minimise
the influence of the release and extracellular metabolism
of nucleotides. We used the perforated-patch clamp tech-
nique to record the Ca2+-dependent, Cl- current (ICl,Ca)
induced by nucleotides in single, acutely dissociated pul-
monary artery smooth muscle cells [4,5]. The pulmonary
vascular bed has well characterised regional differences in
receptor and ion channel distribution, including ICl,Ca
[8,25], so the responses of cells isolated from large and
small pulmonary arteries were compared. In addition to
UTP and UDP, we also applied ATP, an agonist at the
P2Y1,2,4,11 & 12 subtypes [14] and determined the ability of
the P2 antagonists suramin and PPADS to inhibit the
responses evoked by each of the agonists. We found that
at least two P2Y subtypes couple to ICl,Ca, with no appar-
ent regional variation in their distribution. The suramin-
sensitive, PPADS-resistant site activated by ATP most
resembles the P2Y11 receptor. However, the suramin- and
PPADS-insensitive receptor activated by UTP and UDP
does not correspond to any of the known P2Y subtypes.
Methods
Isolated cell preparation
Male Sprague-Dawley rats (150 – 250 g) were killed by the
approved Schedule 1 method of cervical dislocation and
exsanguination. After thoracotomy, the heart and lungs
were removed en bloc, the lungs separated and small (SPA,
200–500 µm id) and large (LPA, 1.0–1.5 mm id) intrapul-
monary arteries dissected out. The arteries were cut open
longitudinally and strips of smooth muscle bathed in a
dissociation medium (DM) composed of (mM); NaCl
110; KCl 5; KH2PO4 0.5; NaH2PO4 0.5; NaHCO3 10; N-[2-
hydroxyethyl]piperazine-N'-[2-ethane-sulfonic acid]
(HEPES)10; phenol red 0.03; taurine 10; ethylenediami-
netetraacetic acid (EDTA) 0.5; MgCl2 2; glucose 10 and
CaCl2 0.16, titrated to pH 7.0 with KOH. After incubation
in DM containing 0.6 – 0.8 mg.ml-1 papain, 0.04% BSA
and 0.4 mM dithiothreitol at 37°C (15 min for LPA, 10
min for SPA), collagenase (0.6 – 0.8 mg.ml-1; type IA) was
added and the tissues incubated for a further 10 (LPA) or
5 (SPA) min. Cells were then dispersed by mild trituration
in enzyme-free solution and used within 7 hours.
Electrophysiological recording
Cells were placed in a 50 µl chamber and superfused at
room temperature with physiological salt solution (PSS)
composed of (mM): NaCl 122; KCl 5; HEPES 10; KH2PO4
0.5; NaH2PO4 0.5; MgCl2 1; glucose 11; CaCl2 1.8; titrated
to pH 7.3 with NaOH. Electrophysiological responses ofRespiratory Research 2005, 6:124 http://respiratory-research.com/content/6/1/124
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isolated smooth muscle cells were studied in the whole-
cell, perforated-patch mode with amphotericin B (150
µg.ml-1) added to a pipette solution of the following com-
position (mM): KCl 125; MgCl2 4; HEPES 10; ethylene
glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
(EGTA) 0.02, titrated to pH 7.3 with KOH. Pipette resist-
ance was 4–8 MΩ. The cells were voltage-clamped at -50
mV using an Axopatch 200A amplifier (Axon Instru-
ments). Data were recorded and analysed with a personal
computer interfaced with a Digidata 1200 A/D converter
(Axon Instruments) using Axotape and pClamp (V5) soft-
ware (Axon Instruments). Current responses to -10 mV
hyperpolarizing steps were used to measure cell
capacitance.
We have reported previously that 10-4 M ATP, UTP and
UDP each evoked pronounced contractions of rat isolated
SPA and LPA and that 10-4 M suramin and PPADS pro-
duced maximum inhibition of these responses [6]. There-
fore, this concentration of these drugs was used here. All
were applied to the cells using a gravity-feed perfusion sys-
tem, for which the time for complete solution exchange
was less than 2 s. Only one agonist was applied to each
cell. P2Y receptor-mediated contractions develop slowly
and take 5–10 min to reach a steady-state plateau, there-
fore, in most cases the agonists were applied to the cells
for 5 min or more.
Electrophysiological analysis
The rat pulmonary artery is a relatively short vessel, with
only a thin layer of smooth muscle cells. Enzymatic disso-
ciation produces a lower yield of cells that are smaller and
often less robust than those from systemic blood vessels.
Consequently, although oscillating inward currents were
observed in response to P2Y receptor agonists in the
majority of cells studied, quantitative analysis was ham-
pered by the short period of time that many cells could be
maintained in the perforated-patch configuration or by
the disappearance of the response during the recording.
Quantitative analysis was applied only to cells that could
be held for 5 min or more and in which the oscillating cur-
rents lasted more than 4 min. In these cells the following
parameters were measured: a) the peak amplitude of each
current (pA), which was normalised against the cell capac-
itance (pF) to control for variations in cell size; b) the rise
time (ms) of the current at each oscillation from baseline
holding current to peak; c) the width of each oscillation
(ms) at the point where it reached 50% of its peak ampli-
tude. For each, the average value during successive 30 s
intervals over a 4 min period was calculated and com-
pared. Finally, the frequency of oscillations (peak.min-1)
was measured as the number of transient currents occur-
ring during successive 1 min intervals over a 4 min period.
To investigate the effects of P2 receptor antagonists on the
currents, some cells were preincubated with antagonist for
5 min before adding an agonist, but in most cases an ago-
nist was applied for 2 min and then suramin or PPADS
were co-applied for a further 2–3 min. The current ampli-
tude and frequency were measured and average values
compared for the 1 min periods immediately before and
after antagonist addition. The data were compared with
control cells where agonist alone was added and the cur-
rents measured over the same time course.
Tension recording
Rat SPA and LPA were dissected out as described above,
cut into rings 5 mm long and mounted horizontally in 1
ml baths on a pair of intraluminal wires [6]. Tissues were
allowed to equilibrate under a resting tension of 0.5 g
(SPA) and 1.0 g (LPA) for 60 min at 37°C in PSS. Tension
was recorded with Grass FT03 isometric force transducers
connected to a MacLab/4e system, using Chart 3.3 soft-
ware (AD Instruments). Cumulative concentration-
response curves to ATP were obtained in rings in the
absence of antagonist (control) or in the presence of a sin-
gle concentration (3 × 10-5, 10-4 or 3 × 10-4 M) of suramin
or PPADS. Contractions generally took 1–4 min to reach
a plateau and are expressed as a percentage of the contrac-
tion induced in the same preparation by 4 × 10-2 M KCl,
which was applied by replacement of the PSS solution
with PSS in which the KCl concentration was raised by
equimolar substitution for NaCl.
Data analysis
Values in the text and figures refer to mean ± S.E.M.. Data
were compared by paired and unpaired t-tests, or one-way
analysis of variance and Tukey's comparison as appropri-
ate. Differences were considered significant when P <
0.05.
Drugs and solutions
ATP (magnesium salt), UDP (sodium salt), UTP (sodium
salt), suramin hexasodium and PPADS tetrasodium
(Sigma/RBI, UK) were dissolved in deionised water as 100
mM stock solutions and diluted in PSS before application
to the cells.
Results
P2Y receptor agonists induce oscillating inward currents
ATP, UTP and UDP (10-4 M) each evoked inward currents
(peak amplitude = 13 – 727 pA) in most SPA (n = 118)
and LPA (n = 117) smooth muscle cells held at -50 mV
(ATP-91%/88%, UTP-91%/93%, UDP-71%/81%, SPA/
LPA respectively). Outward currents or no response were
evoked in the remaining cells, which were not studied fur-
ther. In most cells the inward currents activated in an
oscillating manner (Figure 1). The first current was usually
the largest and subsequent currents decreased inRespiratory Research 2005, 6:124 http://respiratory-research.com/content/6/1/124
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amplitude, with a variable time-course. The peak of the
first current appeared to be larger for ATP than UTP or
UDP (Figure 2), but this was significant only in the SPA (P
< 0.05). For each agonist there was no significant differ-
ence in the amplitude of the first response between the
small and large vessels. The initial current often had a "W-
shaped" profile (Figure 1), but in most cells (85%) the
biphasic profile disappeared by the second, third or
fourth oscillation, such that subsequent currents were
monophasic. ATP, UTP and UDP each evoked this profile
of responses in a similar proportion of cells.
Quantitative analysis of oscillating currents
The decrease in the amplitude of the oscillating currents
during agonist application complicated the quantification
of the effects of P2Y antagonists, so it was necessary to first
quantify the time-course of the currents. In order to be
able to study the effects of both an agonist and antagonist
on the same cell, the analysis was limited to a subpopula-
tion of cells that were maintained under voltage-clamp for
more than 5 min and in which the oscillating currents
lasted for 4 min or more.
In both SPA (Figure 3a) and LPA (not shown), the ampli-
tude of the oscillating currents tended to decrease over
successive 30 s intervals, particularly within the first 2
min, and this was significant for ATP (P < 0.05), UTP (P <
0.01) and UDP (P < 0.05) in the SPA. The oscillations
induced by ATP, UTP and UDP had similar frequencies
(mean≈6–11.min-1), both in SPA (Figure 3b) and LPA
(not shown) and showed no significant change over 4
Oscillating currents induced by P2Y receptor agonists Figure 1
Oscillating currents induced by P2Y receptor ago-
nists. (a) ATP, (b) UTP and (c) UDP (all 10-4 M), added as 
indicated by the horizontal bars, evoked oscillating inward 
currents in smooth muscle cells isolated from SPA (a & c) 
and LPA (b) and voltage-clamped at -50 mV. The insets show 
W-shape currents induced by (a) ATP and (b) UTP. The 
arrow on the left-hand side of each trace indicates zero hold-
ing current.
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Amplitude of the first inward current induced by P2Y recep- tor agonists Figure 2
Amplitude of the first inward current induced by P2Y 
receptor agonists. The mean ± s.e.mean of the peak ampli-
tude of the initial inward currents evoked by 10-4 M ATP, 
UTP and UDP in SPA and LPA isolated smooth muscle cells, 
voltage-clamped at -50 mV, are shown. The number of cells 
for each is indicated in parentheses. *P < 0.05 for responses 
to ATP versus UTP and UDP in SPA.
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min, apart from a small increase in the LPA between the
first and second min after UTP application (P < 0.05). The
currents evoked by ATP in the first 30 s had a rise time of
1.7 ± 0.3 s and width at 50% peak of 2.9 ± 0.4 s (n = 4) in
SPA and 1.5 ± 0.6 s and 2.2 ± 0.3 s (n = 5) respectively in
LPA. The rise time and width at 50% peak then decreased
significantly (P < 0.01) over the next 60–90 s to a steady
state of around 0.8 s in both SPA and LPA. The width at
50% peak of currents evoked by UTP in the first 30 s was
2.1 ± 0.5 s (n = 5) in SPA and 2.1 ± 0.5 s (n = 5) in LPA
and both decreased significantly (P < 0.01) over the next
60–90 s to a steady state of also about 0.8 s. In contrast,
currents evoked by UTP and UDP in SPA and LPA showed
no significant change in rise time and those to UDP in SPA
and LPA showed no significant change in width at 50%
peak, all having a steady-state value of about 0.8 s.
Effects of P2 receptor antagonists
Having quantified the time-course of the agonist-induced
oscillating currents, we then determined the effects of the
P2Y antagonists suramin and PPADS (10-4 M). In most
cells currents were initiated by an agonist, the antagonist
was then coapplied and the currents compared for 1 min
before and after antagonist addition. To take into account
the decline in current amplitude normally seen over this
time-course (~20–40%), the % decrease in amplitude
over the 2 analysis periods was calculated and compared
with that in control cells where agonist alone was added.
Suramin rapidly and reversibly abolished the currents
evoked by ATP in SPA (Figure 4a, 5) and LPA (not shown).
Additionally, ATP did not elicit currents if cells were pre-
incubated with suramin for 5 min (n = 2, not shown). In
contrast, PPADS (10-4 M) had no effect on the amplitude
or frequency of the ATP-induced currents in SPA (Figure
4b, 5) or LPA (not shown). The rise-time and width at
50% peak were also unaffected (not shown). PPADS was
also ineffective if applied for 5 min prior to ATP (n = 2).
Neither suramin nor PPADS had any effect on the ampli-
tude or frequency of the oscillating currents elicited by
UTP or UDP in either SPA or LPA (Figure 4c, 5). The rise-
time and width at 50% peak were also unaffected (not
shown). PPADS (n = 12) and suramin (n = 7) (Figure 4d)
were also ineffective if applied for 5 min before UTP.
Effects of suramin and PPADS on contractions evoked by 
ATP
We have reported previously the effects of suramin and
PPADS on contractions of rat pulmonary arteries induced
by UTP and UDP [6]. Since suramin abolished current
oscillations induced by ATP, but not UTP or UDP, we
investigated if nucleotide-induced contractions showed
the same differential sensitivity. We report that ATP (10-7
- 3 × 10-4 M) evoked concentration-dependent contrac-
tions of the rat SPA (Figure 6). Suramin (3 × 10-5 - 10-4 M)
The amplitude and frequency of oscillating currents induced  by P2Y receptor agonists Figure 3
The amplitude and frequency of oscillating currents 
induced by P2Y receptor agonists. (a) The mean ampli-
tude of oscillating currents induced by ATP, UTP and UDP 
(10-4 M) was measured over successive 30 s intervals for 4 
min in smooth muscle cells isolated from SPA and voltage-
clamped at -50 mV. 0.5 = the first 30 s of agonist application, 
1 = 30 – 60 s, and so on. (b) The frequency of the oscillations 
in the same cells was measured over successive 1 min inter-
vals. 1 = the first min of agonist application, 2 = the second 
min, and so on. Vertical bars represent s.e.mean. The 
number of cells for each agonist is shown in parentheses. * P 
< 0.05 for amplitude of peak current at 30 s versus that at 
2:30, 3:00, 3:30 and 4:00 min; ** P < 0.01 for 30 s versus 3:30 
and 4:00 min.
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The effects of P2 receptor antagonists on oscillating currents Figure 4
The effects of P2 receptor antagonists on oscillating 
currents. The P2 receptor antagonists suramin and PPADS 
(10-4 M) were applied either 2 min after oscillations were 
induced by continuous application of 10-4 M (a, b) ATP or (c) 
UDP or (d) 5 min before application of 10-4 M UTP to SPA (a, 
b) or LPA (c, d) dissociated smooth muscle cells voltage-
clamped at -50 mV. The horizontal bars indicate agonist and 
antagonist applications. The arrow on the left-hand side of 
each trace indicates zero holding current.
The effects of P2 receptor antagonists on oscillating current  amplitude and frequency Figure 5
The effects of P2 receptor antagonists on oscillating 
current amplitude and frequency. The effects of suramin 
and PPADS (10-4 M) on (a) the amplitude and (b) the fre-
quency of oscillating inward currents induced by ATP, UTP 
and UDP (10-4 M) in SPA dissociated smooth muscle cells, 
voltage-clamped at -50 mV, are shown. The agonist was 
applied for 2 min and then suramin or PPADS was coapplied 
for a further 2–3 min. The current amplitude was measured 
for 1 min immediately before and after antagonist addition 
and average values calculated. The % decrease in amplitude 
was then calculated as the difference in the 2 average values. 
The control data were obtained over the same time-course 
in cells where agonist alone was added. The average fre-
quency of oscillations was also measured for 1 min immedi-
ately before and after antagonist addition and compared 
directly. Vertical lines show s.e.mean. The number of cells is 
shown in parentheses.
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caused a progressive rightward shift of the ATP concentra-
tion-response curve and the responses were abolished by
the highest concentration of the antagonist (Figure 6a).
PPADS (3 × 10-5 M) also shifted the ATP concentration-
response curve to the right, but increasing its concentra-
tion to 10-4 M and 3 × 10-4 M) produced no further inhi-
bition (Figure 6b). In rat LPA ATP induced contractions
only at 10-4 M and above [6] and these small contractions
were abolished by 3 × 10-4 M suramin or PPADS (not
shown).
Discussion
The present study shows that ATP, UTP and UDP induce
oscillating inward currents with similar amplitudes and
frequencies in smooth muscle cells of rat pulmonary arter-
ies. Such Cl- currents have been reported previously in
these cells and are dependent upon nucleotide-evoked
release of Ca2+  from sarcoplasmic reticulum stores
[4,5,26]. The P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptors
all couple to the Gq/11 G proteins, leading to the release of
IP3-sensitive Ca2+ stores [14] and so could, if present in
the tissue, mediate activation of ICl,Ca. UTP and UDP both
acted at a site that was insensitive to the antagonists
suramin and PPADS, which may be the P2Y6 receptor or
perhaps a novel receptor. ATP clearly acted via a different
subtype, which most resembles the P2Y11 receptor. There
were few differences apparent between the SPA and LPA,
consistent with our previous conclusion from contractile
studies that there is no regional variation in the P2Y
subtype distribution. Thus, multiple subtypes of P2Y
receptor are widely expressed in pulmonary artery smooth
muscle and are likely to play a role in nucleotide-induced
vasoconstriction.
P2Y receptors in SPA and LPA
In these experiments, the currents evoked by ATP in cells
from the SPA and LPA were abolished by suramin, but
unaffected by PPADS. ATP is an agonist at the P2Y1,2,4 & 11
receptors [15] and the P2Y1 and P2Y4 subtypes can be
ruled out, because PPADS antagonises both of these [4].
The P2Y2 receptor can also be discounted as responses to
the P2Y2 agonist UTP were not inhibited by suramin. The
remaining P2Y11 receptor is antagonised by suramin, but
not PPADS [27], consistent with a role in mediating the
ATP-induced ICl,Ca. This is problematic, however, as the rat
P2Y11 receptor has yet to be cloned. Indeed, it is not clear
that it is present in the rodent genome, although a previ-
ous pharmacological study is also consistent with its
expression in rat blood vessels [28]. Further studies are
required to address this issue. Note that ATP has been
reported to be an agonist at the P2Y12 receptor [29] and
that a contractile P2Y12 receptor was recently reported in
human blood vessels [30]. However, the agonist action of
ATP has been questioned [31] and the P2Y12 receptor cou-
ples to Gi and so is unlikely to induce the release of Ca2+
Effects of suramin and PPADS on contractions evoked by  ATP Figure 6
Effects of suramin and PPADS on contractions 
evoked by ATP. The effects of (a) suramin and (b) PPADS 
on contractions of rat isolated SPA induced by ATP are 
shown. Cumulative concentration-response curves to ATP 
(10-7 - 3 × 10-4 M) were obtained in rings in the absence of 
antagonist (control) or in the presence of 3 × 10-5, 10-4 or 3 
× 10-4 M of antagonist. Contractions are expressed as a per-
centage of the contraction induced by 4 × 10-2 M KCl. Verti-
cal lines show s.e.mean. n = 5 for suramin and 4 for PPADS.
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stores needed to activate ICl,Ca in rat pulmonary arteries
[5].
UTP and UDP also activated ICl,Ca, but the responses were
unaffected by suramin or PPADS. This is consistent with
the lack of effect of the antagonists on UTP- and UDP-
induced vasoconstriction in the rat perfused pulmonary
vascular bed [10] and with the antagonist-insensitive
component of UTP and UDP contraction of isolated pul-
monary artery [6], but contrasts with the abolition by
suramin of UTP-elicited oscillating currents seen
previously in single cells [5,12]. The reason for these dif-
ferences in suramin activity is not clear. Which receptor(s)
mediated the actions of UTP and UDP in the present study
is also unclear. UTP is an agonist at the P2Y2,4 &6 subtypes,
whilst UDP is only active at the P2Y6 receptor [2,15].
Detailed studies show clearly that the P2Y2 receptor is
antagonised by suramin and the P2Y4 receptor by PPADS
(2,20). So, these subtypes do not mediate the effects of
UTP (or UDP) seen here.
If the P2Y2 and P2Y4 receptors are ruled out, then the P2Y6
receptor is the prime candidate for the site of action of
UTP and UDP. Indeed, its mRNA is present in rat
pulmonary artery smooth muscle and it has been pro-
posed to underlie the UDP-induced ICl,Ca [12]. However,
the effects of suramin and PPADS at this site are not well
characterised. In the only study on the cloned rat P2Y6
receptor, 10-4 M suramin (the same concentration used in
the present study) depressed the agonist response by 20%
[32]. Similar inhibition (27%) was seen at the cloned
human P2Y6 receptor [18]. PPADS was not tested at the rat
receptor, but at 10-4 M it inhibited the response to UDP at
the human subtype by 69%. This pronounced effect of
PPADS is inconsistent with the P2Y6 receptor being the
receptor through which UTP and UDP activated ICl,Ca in
the present study. Further characterisation of the effects of
suramin and PPADS at the recombinant rat P2Y6 receptor
is, however, needed to substantiate this conclusion.
If the P2Y2, P2Y4 and P2Y6 receptors are not the site(s) of
action of UTP and UDP, then what is? One possibility is
that UTP and UDP activated ICl,Ca in rat SPA and LPA
smooth muscle via a novel, as yet uncloned P2Y receptor
or another, non-P2Y receptor. For example, UDP has been
proposed to interact with cysteinyl leukotriene receptors
in human mast cells [33,34]. Alternatively, one of the
known P2Y receptors may interact with another P2Y sub-
type, or with a non-P2Y receptor, to form a dimer with
novel pharmacological properties. Indeed, the P2Y1 and
P2Y2 receptors both appear to form dimers with the A1
adenosine receptor [35]. Further studies are needed to
investigate these possibilities.
P2X receptors in SPA and LPA
In this study, the currents evoked by ATP, UTP and UDP
had similar time-courses, as measured by rise time and
width at 50% peak. This may appear surprising as ATP,
but not UTP or UDP, is also an agonist at the P2X1 recep-
tor and so might be expected to activate an initial, rapid,
transient inward current, in addition to the slower, longer
lasting, P2Y-mediated oscillations, as has been reported
previously in rat pulmonary artery smooth muscle cells
[4,5]. The apparent absence of the transient response may
be due to the relatively slow speed of application of ATP
used here. The P2X1 receptor desensitizes rapidly and slow
agonist administration elicits much slower and smaller
currents in vascular smooth muscle cells [36]. Although
this would be disadvantageous if studying P2X receptors,
by minimizing the P2X response it is in fact an advantage
when P2Y receptors are under study. The initial current
evoked by ATP in SPA and LPA may well be a mixture of
P2X1 and P2Y receptor-induced responses, which would
explain the larger amplitude of the initial ATP-induced
current, compared with UTP and UDP. Nevertheless, any
P2X1 component appears to play a relatively minor role
and would not contribute to the sustained phase of
oscillations.
Contribution of P2Y subtypes to contractions
Although the receptors that mediate activation of ICl,Ca by
nucleotides in the rat pulmonary artery have not been
identified unequivocally, we can still consider their role in
vasoconstriction of the rat pulmonary vascular bed [10]
and isolated arteries [6,12,13]. In this study, contractions
of the SPA elicited by ATP were abolished by suramin, but
only partially inhibited by PPADS. The PPADS-resistant
contractions likely reflect release of Ca2+ stores, causing
the ICl,Ca recorded here. They may also involve Ca2+ influx
via L-type Ca2+ channels, opened by depolarisation due to
ICl,Ca. Further experiments using channel blockers are
needed to confirm this. The P2X1 receptor in SPA smooth
muscle [6] is most likely to underlie the remaining
suramin- and PPADS-sensitive component. Interestingly,
contractions of the rat LPA were abolished by both
suramin and PPADS, suggesting that only one receptor,
probably the P2X1  receptor, mediates the contractile
actions of ATP here. This is consistent with the much
lower contractile potency of ATP in LPA [6], but it suggests
that the similar suramin- and PPADS-insensitive ICl,Ca
observed in response to ATP in LPA and SPA may serve
different functions. In our previous study [6] contractions
of rat SPA induced by UTP and UDP were not inhibited by
PPADS and were only partially suppressed by suramin.
These antagonist-resistant contractions again likely reflect
release of Ca2+ stores and activation of ICl,Ca. The identity
of the suramin-sensitive receptors remains to be
determined.Respiratory Research 2005, 6:124 http://respiratory-research.com/content/6/1/124
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Advantages of the patch clamp technique
This study shows that recording ion currents in single cells
can be useful in characterising the receptors expressed in
tissues where multiple subtypes are present. A particular
problem with P2Y receptors is ecto-nucleotidases, which
are inhibited by PPADS in smooth muscle [37] and other
tissues [38,39]. Recording from rapidly perfused, single
cells minimises the problems created by extracellular
metabolism in whole tissues, which may explain why
PPADS potentiated contractions to UTP and UDP in the
intact artery [6], but had no effect on activation of ICl,Ca in
single cells. Such studies also allow the regional variation
in ion channel expression to be studied. Interestingly, we
recorded ICl,Ca in a similar proportion of rat SPA and LPA
smooth muscle cells, whereas in rabbits it is more
predominant in smaller pulmonary arteries [25]. Limita-
tions of the patch clamp technique encountered here were
short recording times, wide variation in current amplitude
between cells and a decline in the amplitude of ICl,Ca over
the recording period, all of which hampered quantitative
analysis of antagonist action. It is not clear why rundown
occurred, as loss of diffusible cytosolic factors into the
recording pipette should have been minimised with the
perforated-patch technique. Similar rundown was seen in
previous patch clamp studies in these cells [4,5] and with
ATP- and UTP-induced oscillations in cytosolic [Ca2+]
[26]. Thus, the decline in ICl,Ca may in fact reflect a physi-
ological mechanism of signalling whereby the P2Y recep-
tors become desensitised and/or intracellular stores
release progressively less Ca2+ during maintained activa-
tion of P2Y receptors.
Conclusion
The results of the present study indicate the presence of at
least two different subtypes of P2Y receptors mediating
oscillating inward currents in rat SPA and LPA smooth
muscle cells. ATP acts via a suramin-sensitive, PPADS-
insensitive site, which most resembles the P2Y11 receptor.
The site of action of UTP and UDP is less clear. Its phar-
macology is inconsistent with our present understanding
of P2Y2,4 & 6 receptors, so a novel receptor or receptor com-
plex may be involved. These different P2Y receptors are
likely to play a significant role in nucleotide-induced pul-
monary vasoconstriction as ATP, UTP and UDP each
induce contractions of the rat pulmonary artery with
matching pharmacological profiles.
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